Reviva Pharmaceuticals (RVPH) Holdings announced that it intends to offer shares of its common stock and warrants to purchase shares of common stock in a public offering. All of the securities to be sold in the offering are to be offered by Reviva. The company currently intends to use the net proceeds from the offering to fund research and development activities and for working capital and other general corporate purposes. A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVPH:
- Reviva Pharmaceuticals Holdings: Positive Phase 3 Data and Favorable Safety Profile Support Buy Rating
- Reviva Pharmaceuticals Completes Phase 3 Study for Schizophrenia
- Reviva Pharmaceuticals announces full dataset for one-year Phase 3 RECOVER study
- Reviva Pharmaceuticals Launches $50M At-Market Offering
- Reviva Pharmaceuticals Reports Q1 2025 Financial Results
